细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5387人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702429, encodeId=bf691e024294f, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, objectType=article, longId=113567, objectId=c69011356e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69011356e79, replyNumber=0, likeNumber=24, createdTime=2018-07-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69011356e79, moduleTitle=伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69011356e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702408, encodeId=f4d41e024089a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, objectType=article, longId=94964, objectId=7a03949644f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a03949644f, replyNumber=0, likeNumber=23, createdTime=2017-10-29, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a03949644f, moduleTitle=一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a03949644f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702450, encodeId=fcaf1e0245075, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, objectType=article, longId=122933, objectId=d3461229331a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3461229331a, replyNumber=0, likeNumber=23, createdTime=2018-06-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3461229331a, moduleTitle=【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3461229331a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702422, encodeId=08b71e0242285, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, objectType=article, longId=107875, objectId=aa2c10e8756a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2c10e8756a, replyNumber=0, likeNumber=64, createdTime=2018-07-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2c10e8756a, moduleTitle=Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa2c10e8756a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702424, encodeId=7f1f1e024243b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V3）, objectType=article, longId=108589, objectId=7e68108589ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e68108589ac, replyNumber=0, likeNumber=18, createdTime=2017-12-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e68108589ac, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2017.V3）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e68108589ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702434, encodeId=45d71e0243427, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, objectType=article, longId=115405, objectId=751111540543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751111540543, replyNumber=0, likeNumber=74, createdTime=2018-04-08, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751111540543, moduleTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=751111540543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702459, encodeId=247c1e024592b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V2）, objectType=article, longId=125479, objectId=39601254e95c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39601254e95c, replyNumber=0, likeNumber=19, createdTime=2018-09-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39601254e95c, moduleTitle=NCCN临床实践指南：T细胞淋巴瘤（2018.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39601254e95c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702414, encodeId=db151e0241451, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet Oncol：弥漫性大B细胞淋巴瘤的高风险年轻患者的治疗研究, objectType=article, longId=103953, objectId=9e52103953a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e52103953a4, replyNumber=0, likeNumber=61, createdTime=2017-11-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e52103953a4, moduleTitle=Lancet Oncol：弥漫性大B细胞淋巴瘤的高风险年轻患者的治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e52103953a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702449, encodeId=6d401e02449f6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=病例分享：淋巴浆细胞淋巴瘤/华氏巨球蛋白血症？一例分析, objectType=article, longId=122594, objectId=886a1225942e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=886a1225942e, replyNumber=0, likeNumber=70, createdTime=2018-03-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=886a1225942e, moduleTitle=病例分享：淋巴浆细胞淋巴瘤/华氏巨球蛋白血症？一例分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=886a1225942e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702456, encodeId=a3561e0245656, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet：acalabrutinib用于治疗复发性/难治性套细胞淋巴瘤的效果和安全性。, objectType=article, longId=123306, objectId=4e3712330674, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e3712330674, replyNumber=0, likeNumber=125, createdTime=2017-12-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e3712330674, moduleTitle=Lancet：acalabrutinib用于治疗复发性/难治性套细胞淋巴瘤的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e3712330674)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702413, encodeId=76f11e0241311, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Cancer Cell：首次揭示T细胞淋巴瘤的表观遗传调控机制, objectType=article, longId=103706, objectId=01b6103e060e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01b6103e060e, replyNumber=0, likeNumber=61, createdTime=2017-11-07, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01b6103e060e, moduleTitle=Cancer Cell：首次揭示T细胞淋巴瘤的表观遗传调控机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01b6103e060e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702436, encodeId=cdcc1e02436b4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, objectType=article, longId=116537, objectId=dd4711653e32, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd4711653e32, replyNumber=0, likeNumber=55, createdTime=2017-10-29, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd4711653e32, moduleTitle=SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd4711653e32)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702430, encodeId=90a01e02430c4, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Histol Histopathol：结外NK/T细胞淋巴瘤中TIM-3和LAG-3的表达分析, objectType=article, longId=113961, objectId=8e1c11396103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e1c11396103, replyNumber=0, likeNumber=70, createdTime=2018-03-20, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e1c11396103, moduleTitle=Histol Histopathol：结外NK/T细胞淋巴瘤中TIM-3和LAG-3的表达分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e1c11396103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702451, encodeId=dab01e0245126, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, objectType=article, longId=122937, objectId=5e1a12293e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e1a12293e5c, replyNumber=0, likeNumber=23, createdTime=2018-06-11, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e1a12293e5c, moduleTitle=【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e1a12293e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702412, encodeId=ff3b1e024127e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Cancer Cell：中国科大等首次揭示T细胞淋巴瘤的表观遗传调控机制, objectType=article, longId=103350, objectId=2cb3103350e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cb3103350e6, replyNumber=0, likeNumber=79, createdTime=2018-06-01, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cb3103350e6, moduleTitle=Cancer Cell：中国科大等首次揭示T细胞淋巴瘤的表观遗传调控机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cb3103350e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702402, encodeId=81351e0240267, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2017 NCCN临床实践指南：T细胞淋巴瘤（2017.V1）, objectType=article, longId=84437, objectId=df7f8443ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df7f8443ecf, replyNumber=0, likeNumber=29, createdTime=2017-02-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df7f8443ecf, moduleTitle=2017 NCCN临床实践指南：T细胞淋巴瘤（2017.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df7f8443ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702439, encodeId=3db61e02439d6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定, objectType=article, longId=117910, objectId=9e7d11e910f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e7d11e910f4, replyNumber=0, likeNumber=62, createdTime=2018-05-11, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e7d11e910f4, moduleTitle=治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e7d11e910f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702404, encodeId=e9e11e0240422, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂, objectType=article, longId=87833, objectId=1fe48e83325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fe48e83325, replyNumber=0, likeNumber=79, createdTime=2017-09-18, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fe48e83325, moduleTitle=TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fe48e83325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702401, encodeId=1ad71e024019b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=2017 NCCN临床实践指南：原发性皮肤B细胞淋巴瘤（2017.V1）, objectType=article, longId=84393, objectId=645f8439375, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=645f8439375, replyNumber=0, likeNumber=21, createdTime=2017-02-21, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=645f8439375, moduleTitle=2017 NCCN临床实践指南：原发性皮肤B细胞淋巴瘤（2017.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=645f8439375)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702425, encodeId=43891e02425d3, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：成人高级别B细胞淋巴瘤与Burkitt淋巴瘤：基因组特征和潜在的治疗靶点, objectType=article, longId=108639, objectId=210c1086392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210c1086392a, replyNumber=0, likeNumber=82, createdTime=2017-12-13, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210c1086392a, moduleTitle=Blood：成人高级别B细胞淋巴瘤与Burkitt淋巴瘤：基因组特征和潜在的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210c1086392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究(SPARK研究, MCL 2001）

2018-07-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

一文纵览│伊布替尼治疗套细胞淋巴瘤的疗效

2017-10-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【2017 ASH】伊布替尼治疗复发/难治性套细胞淋巴瘤的长期随访研究

2018-06-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Haematologica：Brentuximab vedotin治疗复发/难治性系统性间变性大细胞淋巴瘤的大型观察性研究（意大利真实世界研究）

2018-07-19

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：B细胞淋巴瘤（2017.V3）

2017-12-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告

2018-04-08

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：T细胞淋巴瘤（2018.V2）

2018-09-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet Oncol：弥漫性大B细胞淋巴瘤的高风险年轻患者的治疗研究

2017-11-22

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

病例分享：淋巴浆细胞淋巴瘤/华氏巨球蛋白血症？一例分析

2018-03-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet：acalabrutinib用于治疗复发性/难治性套细胞淋巴瘤的效果和安全性。

2017-12-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Cancer Cell：首次揭示T细胞淋巴瘤的表观遗传调控机制

2017-11-07

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

SPARK研究（MCL 2001）：伊布替尼单药治疗硼替佐米治疗后进展的套细胞淋巴瘤患者：一项多中心Ⅱ期研究

2017-10-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Histol Histopathol：结外NK/T细胞淋巴瘤中TIM-3和LAG-3的表达分析

2018-03-20

医者仁心 (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【2017ASH】PA分析——伊布替尼治疗复发/难治性套细胞淋巴瘤中位随访时间3.5年

2018-06-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Cancer Cell：中国科大等首次揭示T细胞淋巴瘤的表观遗传调控机制

2018-06-01

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2017 NCCN临床实践指南：T细胞淋巴瘤（2017.V1）

2017-02-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定

2018-05-11

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

TREAKISYM获批成为低度B细胞非霍奇金淋巴瘤和套细胞淋巴瘤抗癌剂

2017-09-18

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

2017 NCCN临床实践指南：原发性皮肤B细胞淋巴瘤（2017.V1）

2017-02-21

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：成人高级别B细胞淋巴瘤与Burkitt淋巴瘤：基因组特征和潜在的治疗靶点

2017-12-13

科室
- - 订阅+
  - 更多科室
工具
服务